1,4-dihydropyridine enantiomers
September 19, 2009. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References1,4-Dihydropyridine carboxylic acid esters 6-Acyloryalkyl-1,4-dihydropyridine derivatives and a method of effecting vasodilation therewith Dihydropyridine compounds which are substituted in the 4-position by imidazolyl or thiazolyl and their medicinal use N-(substituted piperazino)-1,4-dihydropyridine-3,5-carboxylic acid N-Oxide compounds useful in the treatment of cardiovascular ailments Certain N-substituted-4-aryl-3,5-pyridine dicarboxylates and their antihypertensive use 1,4-Dihydro-2,6-dimethyl-4-(2'-chlorophenyl)-3,5-dicarboxylic acid,methyl or ethyl,trifluoroethyl ester Substituted 1,4-dihydropyridines and their use as medicaments Substituted piperazinyl alkyl esters of 2-amino-4-aryl-1,4-dihydro-6-alkyl-3,5-pyridinedicarboxylates Diaryl piperidine containing esters of 1,4-dihydropyridines and coronary therapeutic use Patent #: 4707486 InventorAssigneeApplicationNo. 401453 filed on 09/19/1989US Classes:514/253.1, The five-membered nitrogen hetero ring has chalcogen as a ring member514/253.11, Chalcogen hetero ring attached directly or indirectly to the piperazine ring by nonionic bonding514/253.13, Having -C(=X)-, wherein X is chalcogen, bonded directly to the additional six-membered nitrogen hetero ring514/318, The additional ring is a six-membered hetero ring consisting of one nitrogen and five carbon atoms544/360, Six-membered ring consisting of one nitrogen and five carbons (e.g., pyridine, etc.)544/364, At least three hetero rings containing546/193, Pyridine ring or partially hydrogenated pyridine ring546/194Carbocyclic ring containingExaminersPrimary: Shen, CeciliaAttorney, Agent or FirmInternational ClassesA61K 031/495A61K 031/44 C07D 401/12 Foreign Application Priority Data1987-03-27 CHAbstractEnantiomerically-pure dihydropyridines of formula I ##STR1## are effective vasodilators useful for treating coronary diseases. They have particularly advantageous properties with regard to extent and controllability of blood pressure lowering, a surprisingly small (and for repeated administration--vanishing) increase in heart rate, excellent bioavailability, high therapeutic index, lack of central side effects, lack of kinetic interactions with other substances, absence of tolerance development, well-balanced physical properties and high stability. A new process for preparing these compounds is also presented.Other References
Field of SearchSix-membered ring consisting of one nitrogen and five carbons (e.g., pyridine, etc.)At least three hetero rings containing Pyridine ring or partially hydrogenated pyridine ring Carbocyclic ring containing The additional ring is a six-membered hetero ring consisting of one nitrogen and five carbon atoms |
| ||||||||||||||
